Medivation cancer drug impresses; shares double
An experimental prostate cancer drug from Medivation Inc helped patients live longer in a late-stage study, sending the company's shares soaring on hopes that it will become a strong contender in an estimated $9 billion market.
View full post on Yahoo! Health News
Cancer, double, drug, impresses, Medivation, Shares